“Circulating cell-free nucleosomes as biomarkers
for early detection of colorectal cancer”
See: www.impactjournals.com/Oncotarget, (advance publications 2017)
Our results show that we are likely to use DNA-associated components
for an early detection of colorectalcancer.
The combination of nucleosomes and protein CEA has a high specificity and moderate sensitivity in the identification of individuals with colorectalcancer.
“Direct detection of early-stage cancers using circulating tumor DNA”
Our results show that DNA mutations in blood samples can identify 71% of those who carry an early stage colon cancer disease.These results are generated in a collaboration between Johns Hopkins University, Baltimore, USA; MoMA, Skejby, DK—and collaborating hospitals in Denmark and the Netherlands.
“Serological biomarkers in triage of FIT-positive subjects?”
Age + a FIT-test + a blood test can identify individuals in risk of colon cancer
—who would bee missed in bowel screening based on a Fit-test, alone—
Our results show that a combination of a screening test for occult blood in stools (FIT),
a biomarker-test based on blood and the person’s age with great accuracy will identify subjects with colon cancer or adenomas.
A result validation:
Biological markers in blood can detect subjects at risk of developing a future cancer disease
Our basic research-hypothesis is presently confirmed as we have shown that:
elevated levels of one or more of four blood-based biological markers relate to an increased risk of developing a cancer disease within few years
The design of our current major project ─ Endoscopy III, Part 2 (2016-2022) ─ is therefore based on the research hypothesis:
A screening with a stool test for occult blood showing “no findings” could be a “false negative response” as a malignant disease intra-or,extracolonic may already be under development (cf. a potential elevated biomarker level)─ hence, more frequent follow-up should be offered to diagnose malignancy in early stages.